10:01AM Seattle Genetics highlights ADCETRIS (brentuximab vedotin) data in relapsed Hodgkin lymphoma and other CD30-positive malignancies at ASH Annual Meeting; long-term follow-up from ADCETRIS Pivotal HL Trial demonstrates an estimated two year survival rate of 65% (SGEN) 25.75 +0.21 : Co summarized ADCETRIS (brentuximab vedotin) data in relapsed Hodgkin lymphoma (HL) and other CD30-positive malignancies from multiple presentations at the 54th American Society of Hematology (ASH) Annual Meeting and Exposition. Highlights include survival data from long-term follow up in a pivotal clinical trial of ADCETRIS in relapsed or refractory HL and a retrospective comparison of overall survival among patients treated with ADCETRIS to those not treated with ADCETRIS following an autologous stem cell transplant (ASCT). In addition, data describe the activity and tolerability of ADCETRIS in the salvage HL setting from an investigator-sponsored trial and in relapsed patients age 60 or over with CD30-positive malignancies, including HL. After a median observation time of approximately 2.5 years from first dose of ADCETRIS, 59 percent of patients (60 of 102 patients) were alive and the median overall survival had not yet been reached. The estimated two year survival rate was 65 percent, including 91 percent for patients who achieved a complete remission. Improved overall survival and progression-free survival correlated with PET (positron emission tomography) evaluation at Cycle four. There was no significant difference in prolonged overall survival in patients whose disease progressed less than or more than one year following ASCT. The only pretreatment factor that was associated with a higher two year survival rate was a baseline ECOG score of 0.
Co also presented preclinical data from SGN-CD33A, an antibody-drug conjugate (ADC) in development for the treatment of acute myeloid leukemia (AML). Co expects to advance SGN-CD33A into a phase I clinical trial in 2013. Key findings included SGN-CD33A induced CD33-specific activity at low doses in a broad panel of AML cell lines and primary AML patient samples, including those resistant to multiple other anti-leukemic agents. SGN-CD33A yielded antitumor activity, durable remissions and improved survival in multiple preclinical AML models.
